Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein–Barr virus vaccine in healthy adults
- 11 June 2007
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 25 (24), 4697-4705
- https://doi.org/10.1016/j.vaccine.2007.04.008
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Stress-associated changes in the steady-state expression of latent Epstein–Barr virus: Implications for chronic fatigue syndrome and cancerBrain, Behavior, and Immunity, 2005
- Direct killing of Epstein-Barr virus (EBV)–infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1Blood, 2004
- CD4+T-Cell Effectors Inhibit Epstein-Barr Virus-Induced B-Cell ProliferationJournal of Virology, 2001
- The Mechanism of Action of Cyclosporin A and FK506Clinical Immunology and Immunopathology, 1996
- Replication-defective recombinant adenovirus expressing the Epstein--Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarinJournal of General Virology, 1993
- Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.The Journal of Experimental Medicine, 1992
- Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vectorJournal of General Virology, 1992
- Validation of a first‐generation epstein‐barr virus vaccine preparation suitable for human useJournal of Medical Virology, 1989
- Recombinant vaccinia virus expressing epstein‐barr virus glycoprotein gp340 protects cottontop tamarins against EB virus‐induced malignant lymphomasJournal of Medical Virology, 1988
- Protection of cottontop tamarins against Epstein–Barr virus-induced malignant lymphoma by a prototype subunit vaccineNature, 1985